Amicus Therapeutics Inc (FOLD):企業の財務・戦略的SWOT分析

◆英語タイトル:Amicus Therapeutics Inc (FOLD) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1673
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Amicus Therapeutics Inc (FOLD) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Amicus Therapeutics Inc (Amicus Therapeutics) is a biotechnology company that focuses on the research, development and commercialization of small molecules drugs and orally administered drugs known as pharmacological chaperones for the treatment of rare and orphan diseases. The company’s lead product, Migalastat HCl, a small molecule is indicated for the treatment of Fabry disease. The other development products in the pipeline include ATB200/AT2221 for the treatment of Pompe disease, Fabry disease, and other lysosomal storage disorders; Migalastat for other conditions; and enzyme replacement therapies for other rare diseases. It has presence in the US, the UK, Ireland, France, the Netherlands, Germany, Spain, Italy and Japan. Amicus Therapeutics is headquartered in Cranbury, New Jersey, the US.

Amicus Therapeutics Inc Key Recent Developments

Mar 23,2020 Amicus Therapeutics confirms business continuity, 2020 strategic priorities and announces proactive efforts to support public health initiatives, patients & employees
Mar 20,2020 Amicus opens gene therapy center focused on Rett Syndrome, Other Rare Diseases
Mar 05,2020 Amicus opens new global research and gene therapy center of excellence in Philadelphia
Mar 02,2020 Amicus Therapeutics announces full-year 2019 financial results and 2020 corporate updates

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Amicus Therapeutics Inc – Key Facts
Amicus Therapeutics Inc – Key Employees
Amicus Therapeutics Inc – Key Employee Biographies
Amicus Therapeutics Inc – Major Products and Services
Amicus Therapeutics Inc – History
Amicus Therapeutics Inc – Company Statement
Amicus Therapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Amicus Therapeutics Inc – Business Description
Geographical Segment: Ex-US
Performance
Geographical Segment: The US
Performance
R&D Overview
Amicus Therapeutics Inc – Corporate Strategy
Amicus Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Amicus Therapeutics Inc – Strengths
Amicus Therapeutics Inc – Weaknesses
Amicus Therapeutics Inc – Opportunities
Amicus Therapeutics Inc – Threats
Amicus Therapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Amicus Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 23, 2020: Amicus Therapeutics confirms business continuity, 2020 strategic priorities and announces proactive efforts to support public health initiatives, patients & employees
Mar 20, 2020: Amicus opens gene therapy center focused on Rett Syndrome, Other Rare Diseases
Mar 05, 2020: Amicus opens new global research and gene therapy center of excellence in Philadelphia
Mar 02, 2020: Amicus Therapeutics announces full-year 2019 financial results and 2020 corporate updates
Feb 07, 2020: AmicusTherapeutics announces presentations and posters at 16th Annual WORLDSymposium 2020
Feb 07, 2020: Amicus Therapeutics announces presentations and posters at 16th Annual WORLDSymposium 2020
Jan 13, 2020: Amicus Therapeutics provides full-year 2020 strategic outlook and financial guidance
Jan 09, 2020: Amicus Therapeutics announces preliminary 2019 Galafold revenue – exceeding upper end of prior guidance
Nov 11, 2019: Amicus Therapeutics announces third quarter 2019 financial results and corporate updates
Oct 10, 2019: Amicus Therapeutics announces preliminary third quarter 2019 revenue and financial outlook at 2019 analyst day
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Amicus Therapeutics Inc, Key Facts
Amicus Therapeutics Inc, Key Employees
Amicus Therapeutics Inc, Key Employee Biographies
Amicus Therapeutics Inc, Major Products and Services
Amicus Therapeutics Inc, History
Amicus Therapeutics Inc, Other Locations
Amicus Therapeutics Inc, Subsidiaries
Amicus Therapeutics Inc, Key Competitors
Amicus Therapeutics Inc, Ratios based on current share price
Amicus Therapeutics Inc, Annual Ratios
Amicus Therapeutics Inc, Annual Ratios (Cont...1)
Amicus Therapeutics Inc, Interim Ratios
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Amicus Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Amicus Therapeutics Inc, Performance Chart (2015 - 2019)
Amicus Therapeutics Inc, Ratio Charts
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Amicus Therapeutics Inc (FOLD):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Serco Group plc:企業の戦略・SWOT・財務情報
    Serco Group plc - Strategy, SWOT and Corporate Finance Report Summary Serco Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Eastman Chemical Company:企業のM&A・事業提携・投資動向
    Eastman Chemical Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Eastman Chemical Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Bank of the West:企業の戦略・SWOT・財務情報
    Bank of the West - Strategy, SWOT and Corporate Finance Report Summary Bank of the West - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Chemed Corp (CHE):企業の財務・戦略的SWOT分析
    Summary Chemed Corp (Chemed) is a diversified company. The company operates through its segments including Vitas and Roto-Rooter. Its Vitas segment provides end-of-life hospice care for heart disease, stroke, multiple sclerosis, lung disease, liver disease, and kidney diseases, among others. Chemed …
  • Teva Pharmaceutical Industries Limited:企業のM&A・事業提携・投資動向
    Teva Pharmaceutical Industries Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Teva Pharmaceutical Industries Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed repo …
  • Holding Slovenske elektrarne doo:企業の戦略的SWOT分析
    Holding Slovenske elektrarne doo - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Dolby Laboratories Inc (DLB):企業の財務・戦略的SWOT分析
    Dolby Laboratories Inc (DLB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Kurabo Industries Ltd (3106):企業の財務・戦略的SWOT分析
    Kurabo Industries Ltd (3106) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Siemens AG (SIE):電力:M&Aディール及び事業提携情報
    Summary Siemens AG (Siemens) is a technology company that offers products and solutions for electrification, automation and digitization. The company offers products, services and solutions for power generation, transmission and distribution; oil and gas production and transportation; medical imagin …
  • Enerjisa Enerji AS:電力:M&Aディール及び事業提携情報
    Summary Enerjisa Enerji AS (Enerjisa Enerji) is a power generation company. The company operates in the business of distribution, and sale of electricity. It provides electricity wholesale and retail services, marketing, products and services development, energy management, and energy consultancy se …
  • French National Institute of Health and Medical Research:医療機器:M&Aディール及び事業提携情報
    Summary French National Institute of Health and Medical Research (INSERM) is a biomedical research institute that conducts research in biology, medicine and public health. The institute offers research in the therapeutic areas of neurosciences, cognitive sciences, neurology, psychiatry, cancer, immu …
  • MMI Holdings Ltd.:企業の戦略・SWOT・財務情報
    MMI Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary MMI Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Valeura Energy Inc (VLE):企業の財務・戦略的SWOT分析
    Valeura Energy Inc (VLE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Tokyo Tatemono Co., Ltd.:企業の戦略・SWOT・財務情報
    Tokyo Tatemono Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tokyo Tatemono Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Cognizant Technology Solutions Corporation:戦略・SWOT・企業財務分析
    Cognizant Technology Solutions Corporation - Strategy, SWOT and Corporate Finance Report Summary Cognizant Technology Solutions Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Genzyme Corp-医療機器分野:企業M&A・提携分析
    Summary Genzyme Corp (Genzyme), a subsidiary of Sanofi, is a biotechnology company that develops specialty treatments targeting rare and special unmet medical needs. Its product pipeline comprises Dupilumab for atopic dermatitis and asthma; Patisiran for familial amyloid polyneuropathy; Isatuximab f …
  • Entergy Corporation (ETR)-エネルギー分野:企業M&A・提携分析
    Summary Entergy Corporation (Entergy) is an integrated energy company that generates, transmits, distributes and sells electricity. The company generates electricity from various sources including natural gas, nuclear, coal, hydroelectric and oil based power plants. Entergy also operates a natural g …
  • BWX Technologies Inc (BWXT):電力:M&Aディール及び事業提携情報
    Summary BWX Technologies Inc (BWXT) is a specialty manufacturer of nuclear components. It designs, engineers, and manufactures precision naval nuclear components, reactors, and nuclear fuel for the US Government. The company also provides special nuclear materials processing and environmental site r …
  • Pivotal Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pivotal Therapeutics Inc (Pivotal Therapeutics) is a pharmaceutical company that develops and markets Omega-3 based therapies and therapeutic products for cardiovascular disorders. The company offers products such as VASCAZEN, a medical food formulated for the dietary management of an Omega- …
  • Valecha Engineering Ltd
    Valecha Engineering Ltd - Strategy, SWOT and Corporate Finance Report Summary Valecha Engineering Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆